Compositions and methods for the diagnosis and treatment of tumor

Abstract

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

1 . A method of inhibiting growth of a cell expressing TAT188, the method comprising contacting the cell with an antibody comprising in a corresponding complementary determining region (CDR) an amino acid sequence having the amino acid sequence of all six of the CDRs in the specific order as found in the antibody secreted by a hybridoma selected from the group consisting of 3B5.1 (ATCC Accession Number PTA-6193), 12B9.1 (ATCC Accession Number PTA-6194), and 12G12.1 (ATCC Accession Number PTA-6195). 
     
     
         2 . The method of  claim 1 , wherein the cell is a cancer cell. 
     
     
         3 . The method of  claim 2 , wherein the cancer cell is selected from the group consisting of breast, colon, rectum, endometrium, kidney, lung, ovary, skin, and liver. 
     
     
         4 . The method of  claim 3 , wherein the cancer cell is a mammalian cell. 
     
     
         5 . The method of  claim 4 , wherein the mammalian cell is a human cell. 
     
     
         6 . A method of detecting the level of TAT188 polypeptide expressed in a test cell relative to a control cell, the method comprising: (a) contacting the test cell and the control cell with an isolated anti-TAT188 antibody comprising in a corresponding complementary determining region (CDR) an amino acid sequence having the amino acid sequence of all six of the CDRs in the specific order as found in the antibody secreted by a hybridoma selected from the group consisting of 3B5.1 (ATCC Accession Number PTA-6193), 12B9.1 (ATCC Accession Number PTA-6194), and 12G12.1 (ATCC Accession Number PTA-6195); (b) detecting binding of the antibody; and (c) determining the relative binding of the antibody to the test and control cell. 
     
     
         7 . The method of  claim 6 , wherein the test cell and control cell are lysed. 
     
     
         8 . The method of  claim 6 , wherein the test cell is in a tissue. 
     
     
         9 . The method of  claim 8 , wherein the tissue is a tumor tissue. 
     
     
         10 . The method of  claim 9 , wherein the tumor tissue is selected from the group consisting of breast, colon, rectum, endometrium, kidney, lung, ovary, skin, and liver. 
     
     
         11 . A method of detecting the level of TAT188 polypeptide or a polypeptide having at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 15 in a test cell relative to a control cell, the method comprising: (a) contacting the test cell and the control cell with an isolated antibody comprising in a corresponding complementary determining region (CDR) an amino acid sequence having the amino acid sequence of all six of the CDRs in the specific order as found in the antibody secreted by a hybridoma selected from the group consisting of 3B5.1 (ATCC Accession Number PTA-6193), 12B9.1 (ATCC Accession Number PTA-6194), and 12G12.1 (ATCC Accession Number PTA-6195); (b) detecting binding of the antibody; and (c) determining the relative binding of the antibody to the test and control cell. 
     
     
         12 . The method of  claim 11 , wherein the level of TAT188 polypeptide in the test cell is greater than that in the control cell. 
     
     
         13 . The method of  claim 12 , wherein the method diagnoses cancer in a tissue containing or having contained the test cell. 
     
     
         14 . The method of  claim 11 , wherein the detecting the level of expression of the polypeptide comprises employing an antibody in an immunohistochemistry analysis.